NeuroBo Pharmaceuticals Inc NRBO

NAS: NRBO | ISIN: US64132R1077   14/11/2024
2,390 USD (-6,64%)
(-6,64%)   14/11/2024

3 september 2024 · NeuroBo to Participate in the H.C. Wainwright 26th Annual Global Investment Conference · Persbericht

14 augustus 2024 · NeuroBo Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Corporate Update · Persbericht

13 augustus 2024 · NeuroBo Pharmaceuticals Completes Enrollment of the SAD Part 1 of Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity · Persbericht

6 augustus 2024 · NeuroBo Pharmaceuticals Announces Joint Research Agreement, Together with Dong-A ST and ImmunoForge to Develop a Long-Acting Once-Monthly Formulation of DA-1726 for the Treatment of Obesity · Persbericht

30 juli 2024 · NeuroBo Pharmaceuticals Announces Exclusive License Agreement with MThera Pharma for NB-01 · Persbericht

11 juli 2024 · NeuroBo Pharmaceuticals to Present at the Emerging Growth Conference in July · Persbericht

26 juni 2024 · NeuroBo Pharmaceuticals Doses First Patient in the MAD Part 2 of Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity · Persbericht

25 juni 2024 · NeuroBo Pharmaceuticals Announces the Closing of up to $70 Million Concurrent Private Placement and Registered Direct Offering Priced At-the-Market Under Nasdaq Rules · Persbericht

24 juni 2024 · NeuroBo Pharmaceuticals Announces up to $70 Million Concurrent Private Placement and Registered Direct Offering Priced At-the-Market Under Nasdaq Rules · Persbericht

22 juni 2024 · NeuroBo Pharmaceuticals' DA-1726 Demonstrated Superiority in Weight Loss, Retention of Lean Body Mass, and Lipid-Lowering Effects Compared to Survodutide, in Pre-Clinical Models · Persbericht

22 mei 2024 · NeuroBo Pharmaceuticals' DA-1241 in Combination with Semaglutide Improves Liver Fibrosis and Demonstrates Additive Hepatoprotective Effects in Pre-Clinical MASH Models Compared to Either Treatment, Alone · Persbericht

9 mei 2024 · NeuroBo Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update · Persbericht

30 april 2024 · NeuroBo to Present Latest Pre-Clinical Data on Cardiometabolic Assets, DA-1241 and DA-1726, Targeting MASH and Obesity, at Scientific Conferences in June · Persbericht

17 april 2024 · NeuroBo Pharmaceuticals Doses First Patient in Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity · Persbericht

1 april 2024 · NeuroBo Pharmaceuticals Completes Enrollment of Part 1 of Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of MASH · Persbericht

28 maart 2024 · NeuroBo Pharmaceuticals Reports Year End 2023 Financial Results and Provides Corporate Update · Persbericht

13 maart 2024 · NeuroBo Pharmaceuticals Receives Safety Review Committee Approval to Continue With Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of MASH · Persbericht

4 maart 2024 · NeuroBo Pharmaceuticals Appoints Seasoned Life Science Executive Marshall Woodworth as Chief Financial Officer · Persbericht

29 februari 2024 · NeuroBo Pharmaceuticals Receives First Site IRB Approval for Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity · Persbericht

12 februari 2024 · NeuroBo Pharmaceuticals to Participate in the BIO CEO & Investor Conference · Persbericht

Mijn selecties